drugset / Trial / NCT04977453
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
Timeline
- Start
- 2021-08-02
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GI-101 | Protein / enzyme biologic | — | Intravenous |
| Subject | GI-101A | Protein / enzyme biologic | — | Intravenous |
| Background | Lenvatinib | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |